These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 30339020)

  • 1. Two-Dimensional Label-Free Affinity Analysis of Tumor-Specific CD8 T Cells with a Biomimetic Plasmonic Sensor.
    Soler M; Li X; John-Herpin A; Schmidt J; Coukos G; Altug H
    ACS Sens; 2018 Nov; 3(11):2286-2295. PubMed ID: 30339020
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chronic TCR-MHC (self)-interactions limit the functional potential of TCR affinity-increased CD8 T lymphocytes.
    Duong MN; Erdes E; Hebeisen M; Rufer N
    J Immunother Cancer; 2019 Nov; 7(1):284. PubMed ID: 31690351
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Decreased binding of peptides-MHC class I (pMHC) multimeric complexes to CD8 affects their binding avidity for the TCR but does not significantly impact on pMHC/TCR dissociation rate.
    Dutoit V; Guillaume P; Ayyoub M; Hesdorffer CS; Luescher IF; Valmori D
    J Immunol; 2003 May; 170(10):5110-7. PubMed ID: 12734357
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interplay between T cell receptor binding kinetics and the level of cognate peptide presented by major histocompatibility complexes governs CD8+ T cell responsiveness.
    Irving M; Zoete V; Hebeisen M; Schmid D; Baumgartner P; Guillaume P; Romero P; Speiser D; Luescher I; Rufer N; Michielin O
    J Biol Chem; 2012 Jun; 287(27):23068-78. PubMed ID: 22549784
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dependence of T cell antigen recognition on T cell receptor-peptide MHC confinement time.
    Aleksic M; Dushek O; Zhang H; Shenderov E; Chen JL; Cerundolo V; Coombs D; van der Merwe PA
    Immunity; 2010 Feb; 32(2):163-74. PubMed ID: 20137987
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Allorestricted T lymphocytes with a high avidity T-cell receptor towards NY-ESO-1 have potent anti-tumor activity.
    Krönig H; Hofer K; Conrad H; Guilaume P; Müller J; Schiemann M; Lennerz V; Cosma A; Peschel C; Busch DH; Romero P; Bernhard H
    Int J Cancer; 2009 Aug; 125(3):649-55. PubMed ID: 19444908
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effector memory and central memory NY-ESO-1-specific re-directed T cells for treatment of multiple myeloma.
    Schuberth PC; Jakka G; Jensen SM; Wadle A; Gautschi F; Haley D; Haile S; Mischo A; Held G; Thiel M; Tinguely M; Bifulco CB; Fox BA; Renner C; Petrausch U
    Gene Ther; 2013 Apr; 20(4):386-95. PubMed ID: 22739387
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The spontaneous CD8+ T-cell response to HLA-A2-restricted NY-ESO-1b peptide in hepatocellular carcinoma patients.
    Shang XY; Chen HS; Zhang HG; Pang XW; Qiao H; Peng JR; Qin LL; Fei R; Mei MH; Leng XS; Gnjatic S; Ritter G; Simpson AJ; Old LJ; Chen WF
    Clin Cancer Res; 2004 Oct; 10(20):6946-55. PubMed ID: 15501973
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Competition of peptide-MHC class I tetrameric complexes with anti-CD3 provides evidence for specificity of peptide binding to the TCR complex.
    Hoffmann TK; Donnenberg VS; Friebe-Hoffmann U; Meyer EM; Rinaldo CR; DeLeo AB; Whiteside TL; Donnenberg AD
    Cytometry; 2000 Dec; 41(4):321-8. PubMed ID: 11084618
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Avidity characterization of genetically engineered T-cells with novel and established approaches.
    Hillerdal V; Boura VF; Björkelund H; Andersson K; Essand M
    BMC Immunol; 2016 Jul; 17(1):23. PubMed ID: 27411667
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quantitative TCR:pMHC Dissociation Rate Assessment by NTAmers Reveals Antimelanoma T Cell Repertoires Enriched for High Functional Competence.
    Gannon PO; Wieckowski S; Baumgaertner P; Hebeisen M; Allard M; Speiser DE; Rufer N
    J Immunol; 2015 Jul; 195(1):356-66. PubMed ID: 26002978
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improved detection of melanoma antigen-specific T cells expressing low or high levels of CD8 by HLA-A2 tetramers presenting a Melan-A/Mart-1 peptide analogue.
    Maeurer MJ; Necker A; Salter RD; Castelli C; Höhn H; Karbach J; Freitag K; Neukirch C; Knuth A; Jäger E
    Int J Cancer; 2002 Jan; 97(1):64-71. PubMed ID: 11774245
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Naturally occurring human lymphocyte antigen-A2 restricted CD8+ T-cell response to the cancer testis antigen NY-ESO-1 in melanoma patients.
    Valmori D; Dutoit V; Liénard D; Rimoldi D; Pittet MJ; Champagne P; Ellefsen K; Sahin U; Speiser D; Lejeune F; Cerottini JC; Romero P
    Cancer Res; 2000 Aug; 60(16):4499-506. PubMed ID: 10969798
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immune escape from NY-ESO-1-specific T-cell therapy via loss of heterozygosity in the MHC.
    Klippel ZK; Chou J; Towlerton AM; Voong LN; Robbins P; Bensinger WI; Warren EH
    Gene Ther; 2014 Mar; 21(3):337-42. PubMed ID: 24451117
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of peptide-major histocompatibility complex tetramers and dextramers for the identification of antigen-specific T cells.
    Dolton G; Lissina A; Skowera A; Ladell K; Tungatt K; Jones E; Kronenberg-Versteeg D; Akpovwa H; Pentier JM; Holland CJ; Godkin AJ; Cole DK; Neller MA; Miles JJ; Price DA; Peakman M; Sewell AK
    Clin Exp Immunol; 2014 Jul; 177(1):47-63. PubMed ID: 24673376
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel approach to the characterization of melanoma associated-peptide-specific CTL lines from Japanese metastatic melanoma patients.
    Akiyama Y; Maruyama K; Tai S; Takikawa M; Ohshita C; Yamamoto A; Yamazaki N; Kiyohara Y; Yamaguchi K
    Int J Oncol; 2008 Sep; 33(3):433-41. PubMed ID: 18695871
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessment of CD8 involvement in T cell clone avidity by direct measurement of HLA-A2/Mage3 complex density using a high-affinity TCR like monoclonal antibody.
    Bernardeau K; Gouard S; David G; Ruellan AL; Devys A; Barbet J; Bonneville M; Chérel M; Davodeau F
    Eur J Immunol; 2005 Oct; 35(10):2864-75. PubMed ID: 16163672
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Peptide-specific CD8+ T-cell evolution in vivo: response to peptide vaccination with Melan-A/MART-1.
    Jäger E; Höhn H; Necker A; Förster R; Karbach J; Freitag K; Neukirch C; Castelli C; Salter RD; Knuth A; Maeurer MJ
    Int J Cancer; 2002 Mar; 98(3):376-88. PubMed ID: 11920589
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dissecting TCR-MHC/peptide complex interactions with A2/peptide multimers incorporating tumor antigen peptide variants: crucial role of interaction kinetics on functional outcomes.
    Dutoit V; Guillaume P; Cerottini JC; Romero P; Valmori D
    Eur J Immunol; 2002 Nov; 32(11):3285-93. PubMed ID: 12555674
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Force-Regulated In Situ TCR-Peptide-Bound MHC Class II Kinetics Determine Functions of CD4+ T Cells.
    Hong J; Persaud SP; Horvath S; Allen PM; Evavold BD; Zhu C
    J Immunol; 2015 Oct; 195(8):3557-64. PubMed ID: 26336148
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.